APROGEN BIOLOGICS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,565 KRW | -0.13% |
|
+5.03% | -46.03% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 257,286 | 327,440 | 524,120 | 360,706 | 200,481 | 190,684 |
| Enterprise Value (EV) 1 | 256,643 | 238,793 | 322,016 | 238,252 | 236,145 | 361,628 |
| P/E ratio | -193 x | -26.6 x | 37.6 x | 45.3 x | 26.5 x | -1.55 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 5.67 x | 6.43 x | 9.83 x | 6.39 x | 3.08 x | 2.18 x |
| EV / Revenue | 5.65 x | 4.69 x | 6.04 x | 4.22 x | 3.62 x | 4.14 x |
| EV / EBITDA | 401 x | -885 x | 378 x | -125 x | -24 x | -7.34 x |
| EV / FCF | 72.7 x | -3.17 x | -10.8 x | -2.45 x | 2.37 x | 25.9 x |
| FCF Yield | 1.38% | -31.6% | -9.23% | -40.8% | 42.1% | 3.87% |
| Price to Book | 1.71 x | 1.33 x | 1.04 x | 0.71 x | 0.7 x | 0.52 x |
| Nbr of stocks (in thousands) | 10,788 | 24,165 | 39,857 | 39,857 | 39,857 | 65,753 |
| Reference price 2 | 23,850 | 13,550 | 13,150 | 9,050 | 5,030 | 2,900 |
| Announcement Date | 3/19/19 | 3/13/20 | 3/12/21 | 3/14/22 | 3/17/23 | 3/13/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 45,395 | 50,904 | 53,320 | 56,482 | 65,190 | 87,364 |
| EBITDA 1 | 640.5 | -269.7 | 851.3 | -1,903 | -9,837 | -49,292 |
| EBIT 1 | -825.6 | -1,930 | -1,081 | -3,975 | -12,241 | -70,690 |
| Operating Margin | -1.82% | -3.79% | -2.03% | -7.04% | -18.78% | -80.91% |
| Earnings before Tax (EBT) 1 | -952.4 | -3,057 | 16,644 | 9,831 | 6,844 | -113,383 |
| Net income 1 | -1,215 | -8,315 | 11,253 | 8,103 | 7,837 | -118,270 |
| Net margin | -2.68% | -16.33% | 21.1% | 14.35% | 12.02% | -135.38% |
| EPS 2 | -123.6 | -510.0 | 350.0 | 200.0 | 190.0 | -1,875 |
| Free Cash Flow 1 | 3,530 | -75,346 | -29,721 | -97,245 | 99,450 | 13,979 |
| FCF margin | 7.78% | -148.02% | -55.74% | -172.17% | 152.55% | 16% |
| FCF Conversion (EBITDA) | 551.11% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | 1,268.96% | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/19/19 | 3/13/20 | 3/12/21 | 3/14/22 | 3/17/23 | 3/13/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 35,664 | 170,944 |
| Net Cash position 1 | 643 | 88,647 | 202,104 | 122,454 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -3.625 x | -3.468 x |
| Free Cash Flow 1 | 3,530 | -75,346 | -29,721 | -97,245 | 99,450 | 13,979 |
| ROE (net income / shareholders' equity) | -1.07% | -1.39% | 4% | 1.53% | 1.02% | -26.2% |
| ROA (Net income/ Total Assets) | -0.28% | -0.41% | -0.14% | -0.4% | -1.19% | -6.94% |
| Assets 1 | 440,847 | 2,006,916 | -8,172,019 | -2,006,084 | -661,085 | 1,704,592 |
| Book Value Per Share 2 | 13,952 | 10,194 | 12,680 | 12,744 | 7,200 | 5,607 |
| Cash Flow per Share 2 | 2,005 | 1,254 | 1,626 | 880.0 | 403.0 | 153.0 |
| Capex 1 | 1,013 | 2,130 | 976 | 796 | 1,284 | 28,088 |
| Capex / Sales | 2.23% | 4.18% | 1.83% | 1.41% | 1.97% | 32.15% |
| Announcement Date | 3/19/19 | 3/13/20 | 3/12/21 | 3/14/22 | 3/17/23 | 3/13/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -46.03% | 74.76M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- A003060 Stock
- Financials Aprogen Biologics Inc.
